Human Molecular Genetics, 2001, Vol. 10, No. 23 2679-2686
© 2001 Oxford University Press
A deep intronic mutation in CDKN2A is associated with disease in a subset of melanoma pedigrees
Genetic Epidemiology Division, ICRF Clinical Centre in Leeds, St James’s University Hospital, Beckett Street, Leeds LS9 7TF, UK
Germline mutations of CDKN2A at 9p21 have been shown to predispose to disease in melanoma pedigrees worldwide. However, there remains a significant proportion of melanoma pedigrees with evidence of linkage to 9p21 in which mutations in CDKN2A have not been detected. Investigation of other potential tumour suppressor genes at 9p21 and the promotor of CDKN2A has been unable to explain genetic predisposition to melanoma in these pedigrees. Here we describe a mutation, IVS2-105 A/G, deep in intron 2 of CDKN2A, detected in six English melanoma pedigrees. The mutation creates a false GT splice donor site 105 bases 5' of exon 3 and has been demonstrated to result in aberrant splicing of the mRNA. This is the most common mutation identified in English families to date. The presence of this deep intronic mutation in a relatively large number of kindreds, indicates that it may account for a significant proportion of 9p21-linked melanoma pedigrees with no detectable mutations in the coding region of CDKN2A. In addition, the identification of one deep intronic mutation in CDKN2A indicates the possibility of the existence of other similar splicing mutations located elsewhere in the CDKN2A introns.
+ To whom correspondence should be addressed. Tel: +44 113 206 4668; Fax: +44 113 242 9886; Email: j.newton-bishop@icrf.icnet.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A M Goldstein, S N Stacey, J H Olafsson, G F Jonsson, A Helgason, P Sulem, B Sigurgeirsson, K R Benediktsdottir, K Thorisdottir, R Ragnarsson, et al. CDKN2A mutations and melanoma risk in the Icelandic population J. Med. Genet., May 1, 2008; 45(5): 284 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Lonning, S Knappskog, V Staalesen, R Chrisanthar, and J. Lillehaug Breast cancer prognostication and prediction in the postgenomic era Ann. Onc., August 1, 2007; 18(8): 1293 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Markovic, L. A. Erickson, R. D. Rao, R. R. McWilliams, L. A. Kottschade, E. T. Creagan, R. H. Weenig, J. L. Hand, M. R. Pittelkow, B. A. Pockaj, et al. Malignant Melanoma in the 21st Century, Part 1: Epidemiology, Risk Factors, Screening, Prevention, and Diagnosis Mayo Clin. Proc., March 1, 2007; 82(3): 364 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Ghiorzo, S. Gargiulo, L. Pastorino, S. Nasti, R. Cusano, W. Bruno, S. Gliori, M. R. Sertoli, A. Burroni, V. Savarino, et al. Impact of E27X, a novel CDKN2A germ line mutation, on p16 and p14ARF expression in Italian melanoma families displaying pancreatic cancer and neuroblastoma Hum. Mol. Genet., September 15, 2006; 15(18): 2682 - 2689. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Laud, C Marian, M F Avril, M Barrois, A Chompret, A M Goldstein, M A Tucker, P A Clark, G Peters, V Chaudru, et al. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma J. Med. Genet., January 1, 2006; 43(1): 39 - 47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Puig, J. Malvehy, C. Badenas, A. Ruiz, D. Jimenez, F. Cuellar, A. Azon, U. Gonzalez, T. Castel, A. Campoy, et al. Role of the CDKN2A Locus in Patients With Multiple Primary Melanomas J. Clin. Oncol., May 1, 2005; 23(13): 3043 - 3051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. P. Larson, Y. Ding, L. S-C. Cheng, C. Lundberg, V. Gagalang, G. Rivas, L. Geller, J. Weitzel, D. MacDonald, J. Archambeau, et al. Genetic Linkage of Prostate Cancer Risk to the Chromosome 3 Region Bearing FHIT Cancer Res., February 1, 2005; 65(3): 805 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Tsao, A. J. Sober, K. B. Niendorf, and A. Zembowicz Case 7-2004 - A 48-Year-Old Woman with Multiple Pigmented Lesions and a Personal and Family History of Melanoma N. Engl. J. Med., February 26, 2004; 350(9): 924 - 932. [Full Text] [PDF]
|
|
|
|
|
|
P. Ghiorzo, L. Pastorino, L. Bonelli, R. Cusano, A. Nicora, S. Zupo, P. Queirolo, M. Sertoli, V. Pugliese, and G. Bianchi-Scarra INK4/ARF germline alterations in pancreatic cancer patients Ann. Onc., January 1, 2004; 15(1): 70 - 78. [Abstract] [Full Text] [PDF]
|
|